We have produced resources about lecanemab for you and your patients. Find out more below. Donanemab (brand name Kisunla®) is a new medication used to treat the very early stages of Alzheimer's ...

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

US researchers behind the new analysis said they hoped the findings would help patients weigh up the potential benefits of ...

Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...

New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

View the live stream, or join us through our Webex meeting link, starting at 7:50 a.m. Wednesday Oregon Health & Science University is dedicated to improving the health and quality of life for all ...

In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come ...

(RTTNews) - Biogen Inc. (BIIB), a biotechnology company and Eisai Co., Ltd. On Friday provided an update on the regulatory review of lecanemab as a treatment for early Alzheimer's disease or AD in ...

These questions will now be discussed at the CHMP meeting in February 2025, before the Commission can take a final decision on the Marketing Authorization Application for lecanemab as treatment ...